Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s
Rhea-AI Summary
Anixa Biosciences (NASDAQ: ANIX) said the USPTO will issue U.S. Patent No. 12,472,205 on November 18, 2025, covering methods to induce immune responses to α-lactalbumin for a breast cancer vaccine.
The patent is exclusively licensed from Cleveland Clinic and, together with related patents, is described as extending foundational IP protection for the vaccine program into the mid-2040s. The company calls the program a preventive immunotherapy that targets a protein usually limited to lactation and also expressed in certain breast cancers.
The announcement notes the vaccine remains investigational and that no FDA-approved breast cancer vaccine currently exists, while citing U.S. projections of breast cancer incidence and mortality for context.
Positive
- USPTO will issue U.S. Patent No. 12,472,205 on Nov 18, 2025
- Patent strengthens IP protection into the mid-2040s
- Exclusive license from Cleveland Clinic for the vaccine technology
- Vaccine targets α-lactalbumin, a 'retired' antigen with limited normal expression
Negative
- No FDA-approved breast cancer vaccine currently exists
- Vaccine remains investigational and not authorized for prevention or treatment
News Market Reaction
On the day this news was published, ANIX declined 4.57%, reflecting a moderate negative market reaction. Argus tracked a peak move of +5.0% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $7M from the company's valuation, bringing the market cap to $145M at that time.
Data tracked by StockTitan Argus on the day of publication.
Patent Extends Protection for Novel Vaccine Targeting a Cancer Projected to Strike Nearly 300,000
"Our breast cancer vaccine program is a cornerstone of our strategy to develop next-generation preventive immunotherapies," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "This new patent meaningfully extends the duration of our intellectual property protection and reinforces our commitment to addressing a disease that affects hundreds of thousands of women each year. With a strong and growing global patent portfolio, we are well-positioned to advance a vaccine that could fundamentally change how we prevent breast cancer in healthy women."
Anixa's breast cancer vaccine, developed in collaboration with Cleveland Clinic, represents a novel approach to the prevention and treatment of breast cancer. The vaccine was invented at Cleveland Clinic, and this patent—along with others related to this technology—has been exclusively licensed to Anixa Biosciences. This patent issuance builds upon the Company's broad and expanding intellectual property portfolio, strengthening foundational patent protection for the breast cancer vaccine program into the mid-2040s.
Despite significant progress in breast cancer treatment, the disease remains the most commonly diagnosed cancer among women worldwide. In
Anixa's investigational vaccine aims to stimulate the immune system to recognize and eliminate pre-malignant and malignant cells expressing α-lactalbumin—while sparing normal tissue. By targeting this "retired" protein, which is generally absent from healthy tissue except during lactation, the vaccine has the potential to minimize off-target effects and provide long-lasting immune protection.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-awarded-key-us-patent-expanding-breast-cancer-vaccine-ip-protection-into-2040s-302612431.html
SOURCE Anixa Biosciences, Inc.
FAQ
What does Anixa (ANIX) announce about a new U.S. patent on November 18, 2025?
How long will Anixa's breast cancer vaccine patent protection extend for ANIX?
Is Anixa's breast cancer vaccine approved by the FDA for ANIX shareholders?
Who invented the vaccine technology licensed to Anixa (ANIX)?
What target does Anixa's vaccine (ANIX) use to prevent breast cancer?
